EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSLACG00000016178
Gene Symbol: BCR
4 Cross references
275 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSLACG00000017180
Gene Symbol: BTK
4 Cross references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSLACG00000006170
Gene Symbol: CCR9
4 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSLACG00000004849
Gene Symbol: LOC102348280
3 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSLACG00000011277
Gene Symbol: CXCR4
4 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLACG00000002983
Gene Symbol: CFTR
4 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSLACG00000011017
Gene Symbol: DNMT1
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSLACG00000018184
Gene Symbol: TOP1
4 Cross references
271 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSLACG00000009250
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSLACG00000004390
Gene Symbol: TOP2B
4 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSLACG00000008577
Gene Symbol: EML4
4 Cross references
212 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSLACG00000011703
Gene Symbol: EPHA2
4 Cross references
124 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).